Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Mol Cancer Res. 2013 Oct 3;11(12):1585–1596. doi: 10.1158/1541-7786.MCR-13-0358

Figure 3. Bevacizumab-resistant tumors upregulate angiogenesis genes in response to chronic anti-VEGF therapy.

Figure 3

(A) Gene expression grid displaying 181 differentially expressed genes between bevacizumab-resistant tumors (n=4) (left column/ A) and bevacizumab-sensitive tumors (n=4) (right column/ B) indicates that higher number genes are upregulated than downregulated in the resistant tumors. Also, there is relatively less heterogeneity in gene expression (black color) among the replicates within each group. (B) Functional interaction network analysis involving differentially expressed genes between bevacizumab-resistant tumors and bevacizumab-sensitive tumors using IPA tool.